{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:58:38Z","timestamp":1790459918253,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Organon USA, Inc., now Merck & Co., Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.contraception.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T00:17:30Z","timestamp":1469146650000},"page":"205-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience"],"prefix":"10.1016","volume":"95","author":[{"given":"Mitchell D.","family":"Creinin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Kaunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip D.","family":"Darney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonja","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Rekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2016.07.012_bb0005","first-page":"57","article-title":"Etonogestrel implant (Implanon) for contraception","volume":"39","year":"2001","journal-title":"Drug Ther Bull"},{"issue":"Suppl. 1","key":"10.1016\/j.contraception.2016.07.012_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/13625180801960012","article-title":"Tolerability and clinical safety of Implanon","volume":"13","author":"Blumenthal","year":"2008","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2016.07.012_bb0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0010-7824(78)90022-7","article-title":"Contraception with long acting subdermal implants: II. Measured and perceived effects in international clinical trials","volume":"18","author":"Coutinho","year":"1978","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.012_bb0020","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.fertnstert.2008.02.140","article-title":"Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials","volume":"91","author":"Darney","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2016.07.012_bb0025","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF03190042","article-title":"Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta","volume":"24","author":"Timmer","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.contraception.2016.07.012_bb0030","series-title":"Risk assessment and risk mitigation review(s)","author":"Department of Health and Human Services, Food and Drug Administration","year":"2014"},{"key":"10.1016\/j.contraception.2016.07.012_bb0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0010-7824(98)00110-3","article-title":"Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon","volume":"58","author":"Wenzl","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.012_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1783\/147118906777888413","article-title":"Migration of Implanon","volume":"32","author":"Ismail","year":"2006","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2016.07.012_bb0050","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.athoracsur.2013.09.029","article-title":"Contraceptive implant embolism into the pulmonary artery","volume":"97","author":"Patel","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.contraception.2016.07.012_bb0055","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.athoracsur.2014.12.049","article-title":"Intravascular pulmonary migration of a subdermal contraceptive implant","volume":"99","author":"D'Journo","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.contraception.2016.07.012_bb0060","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.athoracsur.2014.12.017","article-title":"Subdermal contraceptive implant embolism to a pulmonary artery","volume":"99","author":"O\u2032 Brien","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.contraception.2016.07.012_bb0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.crwh.2015.09.002","article-title":"Migration of a contraceptive subcutaneous device into the pulmonary artery. Report of a case.","volume":"8","author":"Heudes","year":"2015","journal-title":"Case Reports in Women\u2019s Health"},{"key":"10.1016\/j.contraception.2016.07.012_bb0080","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.contraception.2008.06.016","article-title":"Assessment of Implanon insertion and removal","volume":"78","author":"Levine","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2016.07.012_bb0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/AOG.0b013e318259565a","article-title":"Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women","volume":"120","author":"Xu","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2016.07.012_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajog.2012.04.022","article-title":"Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women","volume":"207","author":"Westhoff","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2016.07.012_bb0095","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/AOG.0b013e31828317cc","article-title":"Contraceptive failures in overweight and obese combined hormonal contraceptive users","volume":"121","author":"McNicholas","year":"2013","journal-title":"Obstet Gynecol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416301664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782416301664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:12:40Z","timestamp":1757880760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782416301664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0010782416301664"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2016.07.012","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The US etonogestrel implant mandatory clinical training and active monitoring programs: 6-year experience","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}